BAZEDOXIFENE

Course overview

BAZEDOXIFENE IS A MEDICATION USED IN THE TREATMENT AND MANAGEMENT OF OSTEOPOROSIS. FIRST APPROVED BY THE FDA IN 2013 AS A COMBINATION DRUG, THIS DRUG PRIMARILY TARGETS POSTMENOPAUSAL WOMEN, THE POPULATION MOST SUSCEPTIBLE TO BONE LOSS DEFECTS. BAZEDOXIFENE BELONGS TO A FAMILY OF DRUG COMPOUNDS KNOWN AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISM OF ACTION, ROUTE OF ADMINISTRATION, ADVERSE EVENTS, AND OTHER KEY ELEMENTS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, AND RELEVANT INTERACTIONS) PERTINENT TO HEALTHCARE PROVIDERS IN THE MANAGEMENT OF PATIENTS WITH OSTEOPOROSIS AND RELATED MENOPAUSAL SYMPTOMS.